Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of...

Full description

Bibliographic Details
Main Authors: Nick K Jones, Lucy Rivett, Shaun Seaman, Richard J Samworth, Ben Warne, Chris Workman, Mark Ferris, Jo Wright, Natalie Quinnell, Ashley Shaw, Cambridge COVID-19 Collaboration, Ian G Goodfellow, Paul J Lehner, Rob Howes, Giles Wright, Nicholas J Matheson, Michael P Weekes
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2021-04-01
Series:eLife
Subjects:
SARS-CoV-2
COVID-19
BNT162b2
vaccination
asymptomatic
Pfizer-BioNTech
Online Access:https://elifesciences.org/articles/68808

Internet

https://elifesciences.org/articles/68808

Similar Items